

# Dean J Kereiakes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7701083/publications.pdf>

Version: 2024-02-01

130  
papers

17,099  
citations

47006

47  
h-index

18647

119  
g-index

131  
all docs

131  
docs citations

131  
times ranked

12095  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. <i>New England Journal of Medicine</i> , 2016, 374, 1609-1620.	27.0	3,992
2	Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. <i>New England Journal of Medicine</i> , 2014, 371, 2155-2166.	27.0	1,645
3	Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. <i>Lancet, The</i> , 2016, 387, 2218-2225.	13.7	899
4	Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2010, 362, 1663-1674.	27.0	812
5	Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1735.	7.4	759
6	Enoxaparin vs Unfractionated Heparin in High-Risk Patients With Non- $\sigma$ ST-Segment Elevation Acute Coronary Syndromes Managed With an Intended Early Invasive Strategy. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 45-54.	7.4	702
7	Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2015, 373, 1905-1915.	27.0	554
8	Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020, 382, 799-809.	27.0	520
9	Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2344-2353.	2.8	461
10	Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention. <i>Circulation</i> , 2001, 103, 2572-2578.	1.6	361
11	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. <i>Annals of Internal Medicine</i> , 2015, 163, 40-51.	3.9	357
12	Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. <i>European Heart Journal</i> , 2016, 37, 2252-2262.	2.2	305
13	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. <i>American Heart Journal</i> , 2015, 169, 906-915.e13.	2.7	294
14	1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. <i>Lancet, The</i> , 2016, 387, 1277-1289.	13.7	253
15	Efficacy and Safety of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	3.9	222
16	Randomized Comparison of Everolimus- and Paclitaxel-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2011, 58, 19-25.	2.8	213
17	Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2635-2646.	2.8	209
18	3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2852-2862.	2.8	202

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. <i>BMJ, The</i> , 2013, 347, f6530-f6530.	6.0	194
20	Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus. <i>Circulation</i> , 2011, 124, 893-900.	1.6	188
21	One-Year Clinical Outcomes With SAPIEN 3 Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Severe Aortic Stenosis. <i>Circulation</i> , 2016, 134, 130-140.	1.6	172
22	2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. <i>Lancet, The</i> , 2017, 390, 760-772.	13.7	163
23	Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab. <i>Circulation</i> , 1999, 99, 1951-1958.	1.6	154
24	Three-Year Outcomes With the Absorb Bioresorbable Scaffold. <i>Circulation</i> , 2018, 137, 464-479.	1.6	152
25	Effect of Tricuspid Regurgitation and the Right Heart on Survival After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	3.9	148
26	Abciximab Readministration. <i>Circulation</i> , 2001, 104, 870-875.	1.6	143
27	Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 27.	7.4	135
28	Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2863-2874.	2.8	125
29	Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: An algorithm for percutaneous management. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 52, 279-286.	1.7	122
30	A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1543-1552.	2.8	109
31	Bioresorbable Vascular Scaffolds for Coronary Revascularization. <i>Circulation</i> , 2016, 134, 168-182.	1.6	108
32	Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. <i>Lancet, The</i> , 2018, 392, 1530-1540.	13.7	103
33	The Truth and Consequences of the COURAGE Trial. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1598-1603.	2.8	101
34	Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2213-2223.	2.8	99
35	A Randomized Evaluation of the SAPIEN XT Transcatheter Heart Valve System in Patients With Aortic Stenosis Who Are Not Candidates for Surgery. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1797-1806.	2.9	90
36	Outcomes in Diabetic and Nondiabetic Patients Treated With Everolimus- or Paclitaxel-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2010, 56, 2084-2089.	2.8	85

#	ARTICLE	IF	CITATIONS
37	Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial. <i>European Heart Journal</i> , 2020, 41, 3451-3458.	2.2	78
38	Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up. <i>JAMA Cardiology</i> , 2019, 4, 1261.	6.1	71
39	Clinical and Angiographic Outcomes After Treatment of De Novo Coronary Stenoses With a Novel Platinum Chromium Thin-Strut Stent. <i>Journal of the American College of Cardiology</i> , 2010, 56, 264-271.	2.8	66
40	Prasugrel Plus Aspirin Beyond 12 Months Is Associated With Improved Outcomes After Taxus LibertÃ© Paclitaxel-Eluting Coronary Stent Placement. <i>Circulation</i> , 2015, 131, 62-73.	1.6	60
41	Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption. <i>Circulation</i> , 2019, 140, 1895-1903.	1.6	57
42	A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: Design and statistical methods of the PERSEUS clinical program. <i>Trials</i> , 2010, 11, 1.	1.6	56
43	Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: Final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. <i>American Heart Journal</i> , 2013, 166, 1035-1042.	2.7	51
44	Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1552-1562.	2.9	51
45	Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. <i>EuroIntervention</i> , 2012, 8, 599-606.	3.2	51
46	Percutaneous Coronary Intervention Use in the United States. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 229-235.	2.9	50
47	Safety Profile of a Miniaturized Insertable Cardiac Monitor: Results from Two Prospective Trials. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 1464-1469.	1.2	50
48	The XIENCE nano, everolimus eluting coronary stent system for the treatment of small coronary arteries: The SPIRIT small vessel trial. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 546-553.	1.7	49
49	Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 138-147.	2.9	49
50	Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 121.	1.7	48
51	Primary Results of the EVOLVE Short DAPT Study. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010144.	3.9	48
52	Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. <i>Circulation</i> , 2016, 133, 1772-1782.	1.6	47
53	Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008152.	3.9	44
54	Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1229-1239.	2.9	42

#	ARTICLE	IF	CITATIONS
55	Anticoagulation After Surgical or Transcatheter Bioprosthetic Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1190-1200.	2.8	42
56	Calcific Plaque Modification by Acoustic Shock Waves. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009354.	3.9	42
57	Periprocedural Myocardial Infarction in a Randomized Trial of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 150-156.	3.9	40
58	Planning, Implementation, and Process Monitoring for Prehospital 12-Lead ECG Diagnostic Programs. <i>Prehospital and Disaster Medicine</i> , 1996, 11, 162-171.	1.3	36
59	Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials. <i>EuroIntervention</i> , 2011, 7, 74-83.	3.2	35
60	Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials. <i>EuroIntervention</i> , 2012, 8, 187-195.	3.2	35
61	Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: Design of and rationale for the ABSORB III randomized trial. <i>American Heart Journal</i> , 2015, 170, 641-651.e3.	2.7	34
62	Calcification and extracellular matrix dysregulation in human postmortem and surgical aortic valves. <i>Heart</i> , 2019, 105, 1616-1621.	2.9	33
63	Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. <i>Cardiovascular Diabetology</i> , 2012, 11, 134.	6.8	29
64	Minimizing radiographic contrast administration during coronary angiography using a novel contrast reduction system: A multicenter observational study of the DyeVert, plus contrast reduction system. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1228-1235.	1.7	28
65	A prospective evaluation of the safety and efficacy of TAXUS Element paclitaxel-eluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: the PERSEUS Small Vessel trial. <i>EuroIntervention</i> , 2011, 6, 920-927.	3.2	28
66	Results of an Olmesartan Medoxomil-Based Treatment Regimen in Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2008, 10, 911-921.	2.0	25
67	Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2010, 26, 721-728.	1.9	23
68	The TWENTE Trial in Perspective. <i>JAMA Cardiology</i> , 2017, 2, 235.	6.1	23
69	Evaluation of safety and efficacy of coronary intravascular lithotripsy for treatment of severely calcified coronary stenoses: Design and rationale for the Disrupt CAD III trial. <i>American Heart Journal</i> , 2020, 225, 10-18.	2.7	23
70	Triple-Combination Therapy with Olmesartan, Amlodipine, and Hydrochlorothiazide in Black and Non-Black Study Participants with Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 233-243.	2.2	22
71	Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2018, 205, 110-117.	2.7	22
72	Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 42-49.	2.9	21

#	ARTICLE	IF	CITATIONS
73	First Human Use of RUCâ€4: A Nonactivating Secondâ€Generation Smallâ€Molecule Platelet Glycoprotein IIb/IIIa (Integrin Î±IIbÎ²3) Inhibitor Designed for Subcutaneous Pointâ€ofâ€Care Treatment of STâ€segmentâ€Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020, 9, e016552.	3.7	21
74	Evaluating the Generalizability of a Large Streamlined Cardiovascular Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 96-102.	2.2	20
75	Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study. <i>Circulation</i> , 2022, 145, 97-106.	1.6	20
76	Inflammation as a therapeutic target: a unique role for abciximab. <i>American Heart Journal</i> , 2003, 146, S1-S4.	2.7	19
77	Longâ€Term Efficacy and Safety of Tripleâ€Combination Therapy With Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide for Hypertension. <i>Journal of Clinical Hypertension</i> , 2012, 14, 149-157.	2.0	19
78	Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. <i>Circulation</i> , 2016, 134, 989-998.	1.6	19
79	Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia. <i>Coronary Artery Disease</i> , 2017, 28, 190-197.	0.7	19
80	Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). <i>Circulation</i> , 2017, 135, 1720-1732.	1.6	17
81	A meta-analysis of reduced leaflet motion for surgical and transcatheter aortic valves: Relationship to cerebrovascular events and valve degeneration. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 868-873.	0.8	17
82	Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial. <i>Circulation</i> , 2021, 143, 2143-2154.	1.6	16
83	The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice. <i>American Health and Drug Benefits</i> , 2015, 8, 483-9.	0.5	16
84	Propensity-Matched Patient-Level Comparison of the TAXUS LibertÃ© and TAXUS Element (ION) Paclitaxel-Eluting Stents. <i>American Journal of Cardiology</i> , 2011, 108, 828-837.	1.6	15
85	Percutaneous Interventions for Secondary Mitral Regurgitation. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008998.	3.9	12
86	Efficacy and Safety of the Absorb Bioresorbable Vascular Scaffold in Females and Males. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1881-1890.	2.9	11
87	Evolution of the SYNERGY bioresorbable polymer metallic coronary stent. <i>Future Cardiology</i> , 2018, 14, 307-317.	1.2	11
88	Clinical Implications of Physical Function and Resilience in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Journal of the American Heart Association</i> , 2020, 9, e017075.	3.7	11
89	The direct and indirect effects of the COVID-19 pandemic on cardiovascular disease throughout the world. <i>European Heart Journal</i> , 2022, 43, 1154-1156.	2.2	11
90	Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Lesions: 1-Year Results From the Disrupt CAD III Study. , 2022, 1, 100001.		11

#	ARTICLE	IF	CITATIONS
91	Specialized Centers and Systems for Heart Attack Care. <i>The American Heart Hospital Journal</i> , 2008, 6, 14-20.	0.2	10
92	Dual Antiplatelet Therapy Duration Following Coronary Stenting —. <i>Journal of the American College of Cardiology</i> , 2015, 65, 787-790.	2.8	10
93	Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials. <i>Atherosclerosis</i> , 2018, 277, 211-218.	0.8	10
94	“Back to the Future” for STEMI?. <i>JACC: Case Reports</i> , 2020, 2, 1651-1653.	0.6	9
95	Complete Revascularization. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1432-1435.	2.8	8
96	Bioresorbable vascular scaffolds for the treatment of coronary artery disease. <i>Coronary Artery Disease</i> , 2017, 28, 77-89.	0.7	8
97	Optimal dual antiplatelet therapy duration for bioresorbable scaffolds: an individual patient data pooled analysis of the ABSORB trials. <i>EuroIntervention</i> , 2021, 17, e981-e988.	3.2	8
98	Long-term follow-up of the platinum chromium TAXUS element (ION) stent. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 994-1001.	1.7	6
99	Systemic Pharmacokinetics of Everolimus Eluted From the Absorb Bioresorbable Vascular Scaffold. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2467-2469.	2.8	6
100	Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTEMI-ACS. <i>Journal of Invasive Cardiology</i> , 2003, 15, 536-53.	0.4	6
101	Cultivating Prognosis Following Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1933-1935.	2.8	5
102	Appropriate Use Criteria to Reduce Underuse and Overuse of Revascularization. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2024.	2.8	5
103	Application of Auxiliary VerifyNow Point-of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel $\beta_2$ Receptor Antagonist. <i>TH Open</i> , 2021, 05, e449-e460.	1.4	5
104	Effect of an Olmesartan Medoxomil-Based Treatment Algorithm on Systolic Blood Pressure in Patients with Stage 1 or 2 Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 239-246.	2.2	4
105	Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual) <i>TJ ETQq1 1 0.784314 rgBT<sub>4</sub>/Overlook</i>	1.6	4
106	Safety and Effectiveness of the SVELTE Fixed-Wire and Rapid Exchange Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions: Results of the OPTIMIZE Randomized Study. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010609.	3.9	4
107	Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 285-293.	2.1	3
108	Seated Cuff Blood Pressure-Lowering Efficacy of an Olmesartan Medoxomil-Based Treatment Regimen in Patients with Type 2 Diabetes Mellitus. <i>Drugs in R and D</i> , 2011, 11, 251-257.	2.2	3

#	ARTICLE	IF	CITATIONS
109	Risk Stratification and Timing of Revascularization: Which Patients Benefit from Early Versus Later Revascularization?. <i>Current Cardiology Reports</i> , 2012, 14, 510-520.	2.9	3
110	Impact of High Baseline Left Ventricular Filling Pressure on Transcatheter Aortic Valve Replacement Outcomes in Patients with Significant Mitral Annular Calcification. <i>Journal of the American Society of Echocardiography</i> , 2019, 32, 1067-1074.e1.	2.8	3
111	The OPTIMIZE randomized trial to assess safety and efficacy of the Svelte IDS and RX Sirolimus-eluting coronary stent Systems for the Treatment of atherosclerotic lesions: Trial design and rationale. <i>American Heart Journal</i> , 2019, 216, 82-90.	2.7	3
112	Drug-Coated Balloons for In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1391-1392.	2.8	3
113	Sex-Specific Outcomes After Coronary Intravascular Lithotripsy: A Patient-Level Analysis of the Disrupt CAD Studies. , 2022, 1, 100011.		3
114	Medical and catheter-based therapies for managing stable coronary disease: Lessons from the COURAGE trial. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2009, 11, 45-53.	0.9	2
115	Exercise-induced saphenous vein graft spasm prevented by stenting. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 937-944.	1.7	2
116	PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab. <i>Journal of Clinical Lipidology</i> , 2019, 13, 443-454.	1.5	2
117	Intravascular ultrasound predictors of long-term outcomes following ABSORB bioresorbable scaffold implantation: A pooled analysis of the ABSORB III and ABSORB Japan trials. <i>Journal of Cardiology</i> , 2021, 78, 224-229.	1.9	2
118	Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy. , 2022, 1, 100004.		2
119	Stent Thrombosis. , 2018, , 225-247.		1
120	Very late vasomotor responses and gene expression with bioresorbable scaffolds and metallic drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 723-732.	1.7	1
121	Incidence, Predictors, and Outcomes of Patients Discharged Home Versus Other Medical Facility After Transcatheter or Surgical Aortic Valve Replacement. <i>Structural Heart</i> , 2021, 5, 392-400.	0.6	1
122	“Leave Nothing Behind”. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2850-2852.	2.9	1
123	Individualizing dual antiplatelet therapy (DAPT) duration based on bleeding risk, ischemic risk, or both: An analysis from the DAPT Study. <i>Cardiovascular Revascularization Medicine</i> , 2022, , .	0.8	1
124	In Mildly Symptomatic Patients, Should an Invasive Strategy with Catheterization and Revascularization Be Routinely Undertaken?. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 107-113.	3.9	0
125	Changes in mechanical dyssynchrony in severe aortic stenosis patients undergoing transcatheter aortic valve replacement. <i>Echocardiography</i> , 2019, 36, 243-248.	0.9	0
126	Is two better than one? Re-evaluating the surgical approval process for TAVR. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 68-70.	1.7	0



#	ARTICLE	IF	CITATIONS
127	BVS dÃ©jÃ© vu: the storm before the calm. EuroIntervention, 2020, 16, 623-625.	3.2	0
128	Adjunctive Pharmacotherapy Part II. Journal of Invasive Cardiology, 2009, 21, A6, A9.	0.4	0
129	Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus. , 2022, 1, 100033.		0
130	Coronary Obstruction After Transcatheter Aortic Valve Replacement: From Risk Prediction to Prevention. , 2022, , 100386.		0